Patellar taping does not change the amplitude of electromyographic activity of the vasti in a stair stepping task

S M Cowan, P W Hodges, K M Crossley, K L Bennell

Objective: To investigate the effect of patellar taping on the amplitude of electromyographic activity (EMG) of vasti activation in subjects with and without patellofemoral pain (PFP).

Methods: Ten participants with PFP and 12 asymptomatic controls were recruited to the study. The study was designed as a randomised crossover trial. Participants completed a stair stepping task. Three experimental conditions were assessed: no tape, therapeutic medially directed tape, and placebo vertically directed tape. The main outcome measure was the EMG amplitude of the vastus medialis obliquus and vastus lateralis during the concentric phase of stair stepping.

Results: The application of medially directed therapeutic tape significantly decreased pain in subjects with PFP. However, application of tape over the patella (therapeutic or placebo) did not alter the amplitude of vasti EMG when either the PFP or control participants completed the concentric stair stepping task.

Conclusion: The results of this study indicate that the positive clinical effects of medially directed therapeutic tape are not due to changes in EMG amplitude of the vasti muscle. Thus other effects such as changes in timing of contraction of the vasti are more likely candidates for the mechanism of efficacy.

Methods

Participants

Ten participants diagnosed with PFP by an experienced musculoskeletal physiotherapist and 12 asymptomatic controls were recruited to the study. Control participants were recruited from the staff and student population at the School of Physiotherapy. Participants with PFP were recruited from sports medicine practices, physiotherapists, and sporting clubs. The inclusion and exclusion criteria were based on previous studies and have been reported in full elsewhere.

The participants in this study were also participants in a previously reported study that describes EMG onset timing of the vasti during the stair stepping task.

The study was approved by The University of Melbourne Human Research Ethics Committee. All participants provided written informed consent.

Interventions

Participants underwent three experimental interventions, applied to their dominant (controls) or most painful (PFP group) knee, randomised using a latin square design (therapeutic tape, placebo tape, no tape) within the one testing session. Subjects rested for five minutes between each intervention to ensure that any effect of taping had disappeared before the start of the next task.

Therapeutic taping protocol

Therapeutic taping was applied in a standardised sequence until the participant’s pain was reduced by at least 50% on a 10 cm visual analogue scale during a pain provoking activity. Therapeutic taping procedures included medial glide and tilt, anterior tilt, rotation, and fat pad unloading. Skin protection was provided using a non-rigid, hypoallergenic tape (Fixomull; Beiersdorf Australia, North Ryde, NSW, Australia), and rigid zinc oxide tape (Endura-tape; Victor Endura-Tape, Clareville, Australia) was used to tape the

Abbreviations: EMG, electromyographic; PFP, patellofemoral pain; VL, vastus lateralis; VMO, vastus medialis obliquus

Application of medially directed tape over the patella was originally developed by McConnell as a novel component of treatment for patellofemoral pain (PFP). The original hypothesis was that patellar taping normalised patellar tracking by mechanically shifting the patella in a medial direction. Although the evidence is inconclusive as to whether patellar position is actually altered by the application of tape to the skin, immediate pain relief with patellar taping is well documented.

Mechanisms to explain the apparent pain relieving effect of patellar tape are unclear. It is possible that patellar tape affects the neuromotor control of the vasti. Recent evidence shows that the application of patellar tape alters the relative timing of the vasti in people with PFP. Another aspect of neuromotor control, which may be important, is the relative activation of the vasti. Although McConnell reported preliminary evidence that vastus medialis obliquus (VMO) activity was enhanced with a manual medial glide of the patella during a maximal quadriceps contraction in two asymptomatic subjects, there has been conflicting evidence in the subsequent literature. Two studies have reported differences in the activation of VMO and vastus lateralis (VL) with patellar taping in subjects with and without PFP, others have reported no effects. The inconsistent findings in the literature may be due to factors such as different tasks and differences in the definition of PFP and in the methods used to normalise the electromyographic (EMG) activity. EMG normalisation may be particularly important as this may influence the variability of the data. One method that may be particularly sensitive for detecting differences is to normalise EMG activity to a reference condition without tape. This method has not previously been reported in PFP studies. Previous studies that have normalised EMG amplitude to a maximal contraction in patients with PFP may have failed to find significance because of variability associated with performing a pain provoking activity.

The purpose of this study was to investigate the effect of patellar taping on the amplitude of VMO and VL EMG in patients with PFP and in asymptomatic controls.
patella. All control participants were taped with standard therapeutic taping (medial glide and tilt).

**Placebo taping protocol**

A non-rigid hypoallergenic tape (Fixomull) was applied to the skin in a vertical direction over a flexed knee with the participant sitting. The tape was placed with care such that the alignment of the patella was not visibly altered and to ensure that the knee could be fully flexed without restriction.

**Pain measures**

After each intervention, participants completed a 10 cm visual analogue scale for average pain experienced during the stair stepping task.

**EMG recordings**

Surface electrodes were used to record the EMG activity of VMO and VL. Before electrode placement, electrical impedance was reduced to less than 5 kΩ by shaving, swabbing with alcohol, and gently abrading the skin. Silver/silver chloride electrodes (Graphics Control Corp, Medical Equipment Services, Richmond, Australia) were placed over the muscle bellies of VMO and VL with an interelectrode distance of 22 mm. The VMO electrodes were placed over the muscle belly 40 mm superior to and 30 mm medial to the superomedial patella border and were oriented 55° to the vertical. The VL electrodes were placed 100 mm superior and 60–80 mm lateral to the superior border of the patella and orientated at 15° to the vertical. The ground electrode was placed over the tibial tubercle.

**Movement analysis**

A PEAK movement analysis system (Peak Performance Technology Inc, Englewood, Colorado, USA) was used to identify the concentric phase of the stair stepping task and the time taken to complete the phase (heel strike to toe off). Movement data were sampled at 50 Hz using a single camera placed perpendicular to the centre of the lateral side of the stair apparatus.

**Stair apparatus**

The stairs were placed in the centre of a 5 m walkway. The dimensions of the stairs were based on a previous study and consisted of a 60 cm platform with two steps of 20 cm height on both sides.

**Procedure**

Participants completed a stair stepping task at a rate of 96 steps per minute paced by an external metronome. EMG activity of VMO and VL was recorded during the stance phase of the middle step during ascent and descent for five consecutive trials for each intervention.

EMG data were pre-amplified (×1), band pass filtered at 20–500 Hz, sampled at 1 kHz, and 12 bit A–D converted (Associative Measurement Pty, Ltd, North Ryde, NSW, Australia).

**EMG data analysis**

Root mean square EMG amplitude was calculated for 200 milliseconds after the onset of EMG which was identified and reported previously. The 200 millisecond window was chosen as it was found to be representative of the concentric contraction in most participants. EMG amplitude in the placebo tape and therapeutic tape conditions was expressed as the percentage change in activity from the amplitude recorded in the control condition without application of tape. This form of analysis indicates a change in the activity of the muscles due to the application of tape and removes the need to normalise the EMG to a maximal contraction. In addition, the EMG activity ratio of VMO to VL was calculated for no tape, placebo tape, and tape condition. The assessor of the EMG data was blinded to group allocation, taping condition, and muscle. EMG data were analysed for the concentric phase of the stair stepping task only.

**Statistical analysis**

All data were analysed using Statistical Package for Social Sciences (SPSS; Norusis/SPSS Inc, Chicago, Illinois, USA). The data were assessed for normality and homogeneity of variance.

**Relative magnitude of vasti activity**

A three way (group x taping condition x muscle) mixed measures analysis of variance was used to compare the percentage change of taping conditions (placebo and therapeutic) between muscles (VMO and VL) and groups (PFP and control). The α level was set at p<0.05.

**EMG activity ratio**

The EMG activity ratio of VMO to VL was calculated (EMG activity ratio = VMO/VL). Separate repeated measures analysis of variance were used to compare the effect of taping (no tape, control tape, therapeutic tape) in the two groups (PFP and control). The α level was set at p<0.05.

**Pain measures**

Separate repeated measures analysis of variance were used to compare average pain levels for the three taping conditions in the PFP group and to compare the time taken to complete the stair stepping task between conditions. Post hoc paired t tests were used to determine specific differences.

**Correlations**

Univariate correlations were sought between the percentage change in vasti activity, pain, change in onset timing (using the previously published data set), baseline onset timing, age, height, weight, and sex.

**RESULTS**

The basic data (mean (SD)) for the participants with PFP were: age 23.0 (8.0) years; height 1.67 (0.10) m; weight 59.3 (10.1) kg; body mass index 21.10 (1.82) kg/m². The same data for the control participants were: 19.5 (1.4) years, 1.71 (0.11) m, 60.8 (8.1) kg and 20.75 (1.39) kg/m². Independent t tests revealed no significant differences between the two groups for these variables.

**Adverse reactions**

No participant reported adverse symptoms while wearing either form of tape, nor did the investigator observe any adverse skin responses.

**Pain measures**

When participants with PFP completed the stair stepping task, they had a mean (SE) pain of 3.5 (0.5). In the PFP group, therapeutic taping of the patellofemoral joint resulted in changes in the mean pain reported by the participants as they completed the stair stepping task (p<0.0001). Pain was significantly less in the therapeutic taped condition than in both the placebo (p<0.0001) and no tape condition (p<0.0001). There was no difference between the no tape and placebo taped condition (p = 0.591). There were no differences in the time taken to complete the stair stepping task between taping conditions in either group (p = 0.634).

**Relative magnitude of vasti activation**

Table 1 summarises the changes in EMG activity for the PFP and control participants with therapeutic taping. Figure 1...
shows the percentage change in vasti activity that occurred with therapeutic and placebo tape in the PFP and control participants. The mixed analysis of variance revealed that there were no differences between the control and PFP group (p = 0.215), there were no differences between muscles (p = 0.136) or taping conditions (p = 0.784), and there were no significant interactions between muscle and group (p = 0.472), tape and group (p = 0.115), muscle and tape (p = 0.232), or muscle, tape, and group (p = 0.227).

EMG activity ratio
Figure 2 shows the EMG activity ratio (VMO/VL) in the three taping conditions for the control and PFP groups. The repeated measures analysis of variance revealed no differences between taping conditions in either the control (p = 0.171) or the PFP group (p = 0.256).

Correlations
No single factor or combination of factors were found to predict change in the amplitude of EMG activation of the vasti with the application of therapeutic or placebo tape. There were no significant correlations between the change in vasti activity levels and EMG baseline and change in onset timing differences, pain or age, height, weight, and sex.

DISCUSSION
This study found that taping had no consistent effect on the relative magnitude of activation of the vasti in participants with PFP, despite the fact that tape altered both pain and EMG onset timing in the same population.10 Thus the findings do not support the hypothesis that changes in the relative activation of the vasti with therapeutic patellar tape may be responsible for the well documented pain relief associated with patellar taping.

The finding that therapeutic taping did not affect the magnitude of vasti activation in subjects with PFP agrees with the findings of a number of previous studies.7 14 15 There are a number of possible explanations for the lack of change in EMG activation levels with patellar tape. Firstly, patellar tape may improve the lever arm of the quadriceps through a change in knee flexion angle. A change in knee flexion angle with patellar taping9 may have placed the vasti in a more optimal position for force generation. This improved length tension relation may have been reflected by a change in EMG onset timing, and, as a result, more quadriceps force could have been generated at the same muscle activation level. This may have resulted in the change of EMG onset timing (or vice versa), which may contribute to an increased knee extensor moment without an increase in quadriceps force. Although quadriceps force was not measured in the present study, knee extensor moment has been found to improve with patellar tape.8 25 26 Secondly, the application of therapeutic tape may have resulted in a different lower limb muscle strategy to accomplish the task, which may be reflected in the change in EMG onset timing of the vasti without a change in the level of vasti activation. This could be further investigated with the assessment of other lower limb muscles, such as the vastus intermedius, rectus femoris, gluteals, hamstrings, and calf muscles, and the assessment of three dimensional kinematics all of which may have contributed to a change in strategy and a change in timing with the application of tape.
The findings contrast with a number of studies that have found that patellar tape affects the magnitude of activation of the vasti in PFP.12–13 However, one of these papers is presented only in abstract form, making detailed critique of their methods difficult. Ng et al14 used a ratio of VMO to VL and found patellar taping actually decreased the activation of VMO, which is in contrast with the proposed effect of patellar tape to increase VMO activity. The authors explain that this confounding result may be related to the mechanical effect of tape but that further investigation is required. Also worthy of consideration is that all participants may not respond in the same way to application of therapeutic tape, and thus a group effect may not be found unless responders and non-responders can be identified a priori. Indeed seven of the 10 participants with PF responded positively to the application of therapeutic tape—that is, increased the amplitude of VMO—with a mean increase in this group of 34%. However, statistical analysis did not identify predictive factors for those who responded positively.

The finding that patellar tape did not affect the magnitude of activation of the vasti in control participants concurs with our previous research, which found that patellar taping does not affect EMG onset timing in asymptomatic people.29 This may be because they generally already have an optimal strategy, and, to have an effect on the magnitude of activation, a deficit must exist to begin with.

The vertical untensioned taping procedure was included to control for a placebo effect. The study shows that placebo tape did not affect vasti activity, which is in agreement with previous studies that have found that placebo taping does not change the level of activation of VL, pain, or EMG onset timing.29 However, a limitation with the placebo taping procedure used in this study relates to the fact that the tape was not placed over the same area of skin as the therapeutic tape.

Limitations
It is possible that a true difference in EMG activity between taping conditions does exist but was not detected with our small sample size and relatively large variability (the observed power at α = 0.05 was 0.11). However, a post hoc power analysis (α = 0.05 power = 0.8) revealed that a sample size of greater than 175 subjects would be required for the observed difference of 16% seen with the application of therapeutic tape to be significant. Even with a significant difference, the clinical relevance of such a small difference in EMG activity is perhaps questionable.

Another possible cause of the failure to find a difference in EMG activity levels with therapeutic taping relates to the method of magnitude determination. It is possible that the technique used was insensitive to detect the size of change observed in this study. The technique uses the untaped condition as a reference point for “normal” EMG activity. As the electrodes were not removed between taping conditions, any effect of therapeutic tape or placebo tape would be seen as a change in the activity of VMO or VL relative to the untaped condition. Thus the change can be expressed as a percentage change. This technique has previously only been used in asymptomatic populations,29–30 but theoretically should be very sensitive to change. To explore the possibility that a relative change in the magnitude of vasti activation occurred, the amplitude of VMO was compared directly with that of VL. However, this also failed to show any significant changes. Another possibility is that the application of tape may have stretched the skin, moving it with respect to the muscle so that a different area of the muscle was being recorded after the application of tape. Lastly, the possibility of carry over effects from the different taping conditions cannot be conclusively ruled out because of the small sample size and Latin square design.

CONCLUSION
The results of this study provide further insight into the effect of patellar taping on neuromotor control of the vasti. The finding that patellar taping had no effect on the levels of magnitude of vasti activation in both painful and non-painful subjects supports most previous research and indicates that the positive clinical effects of medially directed therapeutic tape are not due to changes in EMG amplitude of the vasti muscle. Thus other effects such as changes in timing of contraction of the vasti are more likely candidates for the mechanism of efficacy.

REFERENCES

What this study adds
- This study provides further evidence that patellar tape does not change vasti activity in people with patellofemoral pain.
- A within subject design allows electromyographic data to be normalised without the use of painful maximal contraction, which can add to data variability.

What is already known on this topic
- Controversy exists as to whether patellar tape can alter the magnitude of activation of the vasti in people with patellofemoral pain.
- One possible explanation for the inconsistent findings in the literature may be the different techniques used to normalise electromyographic activity of the vasti.

www.bjsportmed.com


Harrison EL, Shepard MS, McQuarrie AM. A randomised controlled trial of physical therapy treatment programs in patellofemoral pain syndrome. Physiother Canada 1999;93–100.


Patellar taping does not change the amplitude of electromyographic activity of the vasti in a stair stepping task
S M Cowan, P W Hodges, K M Crossley and K L Bennell

Br J Sports Med 2006 40: 30-34
doi: 10.1136/bjsm.2005.018499